Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC

Adjuvant Entecavir or Tenofovir for Hepatitis B Virus Related Hepatocellular Carcinoma After Curative Hepatic Resection

This study aims to compare the effect of antiviral therapy with entecavir or tenofovir for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Included patients will randomly divide into two groups.

Hepatocellular carcinoma (HCC) is associated with a poor prognosis, and its incidence has increased dramatically in many countries. Hepatectomy is a radical therapy for early-stage HCC. However, even after radical resection, the prognosis for HCC patients remains discouraging because of the high recurrence rate and frequent incidence of intrahepatic metastasis. Therefore, preventing HCC recurrence is very important.

Hepatitis B virus (HBV) infection is the major risk factor for HCC development in China. Some retrospective studies have shown that tenofovir or entecavir treatment for HBV-related HCC patients can effectively reduce the HCC recurrence rate and increase the survival rate after hepatectomy. However, which drug has more efficacy has not been addressed.

Inclusion Criteria:

• Underwent hepatic resection.
• Diagnosis of HCC was confirmed by postoperative histopathology.
• Positive of HBsAg, HBeAg, or HBV DNA.
• Child-Pugh A or B liver function.

Exclusion Criteria:

• Anti-HCV(+)
• Diagnosis of HCC was not confirmed by postoperative histopathology of surgical samples after surgery.